泽维梅西尼,一个小西格玛-2受体选择性调节器,用于阿尔茨海默氏病
Isabel Iriepa1,2, Marialessandra Contino3, Carmen Abate3
1Departamento de Química Orgánica y Química Inorgánica, Instituto de Investigación Química "Andrés M. del Río" (IQAR), Universidad de Alcalá, 28805-Alcalá de Henares, Madrid, Spain.
一种新型小分子Zervimesine穿过血脑屏障并选择性调节S2R. 它显示出保护突触和神经元免受有毒的粉样β oligomers 的潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 可溶性粉样β (Aβ) 寡合物与突触和神经元损伤有关.
- 在神经退行性疾病中,开发保护Aβ毒性的治疗方法至关重要.
研究的目的:
- 为了研究Zervimesine的神经保护潜力.
- 描述Zervimesine作为S2R调节器的药理学特征.
主要方法:
- 通过有机化学合成Zervimesine.
- 对血脑屏障透的评估.
- 评估S2R调制的选择性和强度.
- 在神经元模型中测试Zervimesine对可溶性Aβ寡合物的疗效.
主要成果:
- 泽维米素是一种易于合成的小分子,具有最小的目标外影响.
- 它表现出强大的和选择性的S2R调制.
- 泽维米素证明了保护突触和神经元免受有毒的Aβ寡合物的能力.
结论:
- 泽维梅西因是一种有前途的神经保护剂.
- 它的S2R调节器活性可能是其预防Aβ诱导神经毒性的基础.
更多相关视频
06:41Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
相关概念视频
Alzheimer's Disease: Treatment
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Drugs Affecting Neurotransmitter Release or Uptake
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
